Elijah E. Cummings Family Asthma Act

1) What happened: On November 17, 2025, Rep. Debbie Dingell (D-MI) introduced HR6052 in the House. The bill was referred to the Energy and Commerce Committee and has not advanced further. It has four cosponsors, all in the House, and remains in early legislative stage. 2) The money trail: The bill amends the Public Health Service Act to direct research activities but authorizes zero specific funding. Authorization without appropriation means no actual money is allocated. For market impact, a separate appropriations bill would be needed, which has not been introduced. The total addressable market for asthma treatments ($81.9B annual cost cited in findings) is unaffected by this procedural bill. 3) Structural winners and losers: This bill's passage would not change current law regarding asthma research funding, treatment guidelines, or insurance coverage. No public company's revenue stream is directly affected. Asthma-related tickers (e.g., $TEVA, $GSK, $AZN for inhalers; $REGN for biologics) are not impacted because the bill does not mandate coverage changes, pricing reforms, or new subsidies. 4) Competitive landscape: No real market data provided. The asthma treatment market continues to be driven by FDA approvals, patent expirations, and insurance coverage policies—none of which this bill addresses. 5) Timeline: The bill must pass committee, then the full House, then the Senate (or have a companion bill introduced), then be signed into law. With no companion bill and only four cosponsors, passage in the 119th Congress is uncertain. Even if passed, market impact would be zero without an appropriations bill.